logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Metastatic Castrationresistant Prostate Cancer

    FiltersReset Filters
    4 results

    • jevtana

      (cabazitaxel)
      Sanofi-Aventis U.S. LLC
      Usage: JEVTANA® is indicated for use in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have previously undergone treatment with a docetaxel-containing regimen.

    • rubraca

      (rucaparib)
      Clovis Oncology, Inc.
      Usage: Rubraca is indicated for maintenance treatment of adult patients with BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor therapy and taxane chemotherapy.

    • yonsa

      (abiraterone acetate)
      Sun Pharmaceutical Industries, Inc.
      Usage: YONSA is indicated for use in combination with methylprednisolone to treat patients with metastatic castration-resistant prostate cancer.

    • zytiga

      (abiraterone acetate)
      Janssen Biotech, Inc.
      Usage: ZYTIGA is indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC) when used in combination with prednisone.